Do the downloads!! Share!! The diffusion of very important information and knowledge is essential for the world progress always!! Thanks!!
- – > Mestrado – Dissertation – Tabelas, Figuras e Gráficos – Tables, Figures and Graphics – ´´My´´ Dissertation @ #Innovation #energy #life #health #Countries #Time #Researches #Reference #Graphics #Ages #Age #Mice #People #Person #Mouse #Genetics #PersonalizedMedicine #Diagnosis #Prognosis #Treatment #Disease #UnknownDiseases #Future #VeryEfficientDrugs #VeryEfficientVaccines #VeryEfficientTherapeuticalSubstances #Tests #Laboratories #Investments #Details #HumanLongevity #DNA #Cell #Memory #Physiology #Nanomedicine #Nanotechnology #Biochemistry #NewMedicalDevices #GeneticEngineering #Internet #History #Science #World
Pathol Res Pract. 2012 Jul 15;208(7):377-81. doi: 10.1016/j.prp.2012.04.006. Epub 2012 Jun 8.
The influence of physical activity in the progression of experimental lung cancer in mice
Renato Batista Paceli 1, Rodrigo Nunes Cal, Carlos Henrique Ferreira dos Santos, José Antonio Cordeiro, Cassiano Merussi Neiva, Kazuo Kawano Nagamine, Patrícia Maluf Cury
- PMID: 22683274
- DOI: 10.1016/j.prp.2012.04.006
Impact_Fator-wise_Top100Science_Journals
GRUPO_AF1 – GROUP AFA1 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
GRUPO AFAN 1 – GROUP AFAN1 – Anaerobic Physical Activity – Atividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
GRUPO_AF2 – GROUP AFA2 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
GRUPO AFAN 2 – GROUP AFAN 2 – Anaerobic Physical Activity – Atividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
Slides – mestrado – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
CARCINÓGENO DMBA EM MODELOS EXPERIMENTAIS
DMBA CARCINOGEN IN EXPERIMENTAL MODELS
Avaliação da influência da atividade física aeróbia e anaeróbia na progressão do câncer de pulmão experimental – Summary – Resumo – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
https://pubmed.ncbi.nlm.nih.gov/22683274/
Abstract
Lung cancer is one of the most incident neoplasms in the world, representing the main cause of mortality for cancer. Many epidemiologic studies have suggested that physical activity may reduce the risk of lung cancer, other works evaluate the effectiveness of the use of the physical activity in the suppression, remission and reduction of the recurrence of tumors. The aim of this study was to evaluate the effects of aerobic and anaerobic physical activity in the development and the progression of lung cancer. Lung tumors were induced with a dose of 3mg of urethane/kg, in 67 male Balb – C type mice, divided in three groups: group 1_24 mice treated with urethane and without physical activity; group 2_25 mice with urethane and subjected to aerobic swimming free exercise; group 3_18 mice with urethane, subjected to anaerobic swimming exercise with gradual loading 5-20% of body weight. All the animals were sacrificed after 20 weeks, and lung lesions were analyzed. The median number of lesions (nodules and hyperplasia) was 3.0 for group 1, 2.0 for group 2 and 1.5-3 (p=0.052). When comparing only the presence or absence of lesion, there was a decrease in the number of lesions in group 3 as compared with group 1 (p=0.03) but not in relation to group 2. There were no metastases or other changes in other organs. The anaerobic physical activity, but not aerobic, diminishes the incidence of experimental lung tumors.
Copyright © 2012 Elsevier GmbH. All rights reserved.

SearchSearch
Join Biotech Brothers

Purchase Ebook
Ever wonder how to break into the biotech industry? This is the booklet you need!
$2.99BIOPHARMABIOPHARMACEUTICALSBIOTECHBIOTECH BILLIONAIREBIOTECH HUBBREAKING IN BIOTECHCAPITALFORMAFORMA THERAPEUTICSPHARMAPHASE 1/2PHASE IPKRSICKLE CELL DISEASESTART UPSTARTUPSTHERAPEUTICSVENTURE CAPITALIST
Forma Therapeutics Raises $100 Million in Series D Financing
BY BIOTECHBROTHERSDECEMBER 22, 2019COMMENTS 0

FORMA Therapeutics, a biopharmaceutical company headquartered in Massachusetts, just sent out a press release announcing that the company raised $100 Million (Yes, a hundred million :O). A monstrous round in Series D Financing will fuel the development of their therapy FT-4202 and FT-7051 that is treating patients suffering from rare blood disorders.
FORMA’s FT4202 may potentially play a critical role for being the next therapy for sickle cell. By targeting the mechanism of action that often leads to the development of blood disorders in patients, one can reverse and prevent the development of sickle cell disease. Patients who suffer from this disease tend to have a deficiency of PKR. FORMA’s investigational drug addresses this issue by being an activator for pyruvate kinase RNA (PKR). The activation leads to PKR activation and the binding of hemoglobin to oxygen for these patients.
In a research paper, Allosteric inhibitors of pyruvate Kinase, pyruvate kinase activators can be used potentially as a pharmaceutical treatment for patients with PK deficiency. Because kinase influences the metabolic process and glycolytic pathway, 2,3-diphosphoglycerate, a protein critical in letting hemoglobin to have the affinity it needs to bind with oxygen.
Most drugs that are produced by pharmaceuticals and biotechnology companies try to treat the symptoms of the disease. By reversing and preventing the development of this disease, an activator of PKR can potentially give better results for patients with rare hematologic disorders.
We are no longer creating traditional drugs that just treat the symptoms of a patient, BUT RATHER we are now looking at the underlying cause of a disease.
Don’t forget to subscribe to Biotech Brothers!AdvertisementsREPORT THIS ADAdvertisementsREPORT THIS AD
SHARE THIS:
TAGSFEATURED
ABOUT BIOTECHBROTHERS
A biotechnology and sci fi nerd, that enjoys writing about new innovations within the science world and industry.biotechbrothers.wordpress.com
0 COMMENTS ON “FORMA THERAPEUTICS RAISES $100 MILLION IN SERIES D FINANCING”
LEAVE A REPLY
ciencia100: You are commenting using your WordPress.com account. ( Log Out / Change )
Notify me of new comments via email.
Notify me of new posts via email.
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Post navigation
Like our Facebook Page!
Ebook: Breaking into Biotech

Purchase Ebook
Ever wonder how to break into the biotech industry? This is the booklet you need!
$2.99
KNOWLEDGE EMPOWERS
Search for:
Follow Us
Related

Novartis Acquires The Medicines Company for $9.7 Billion

An Enzyme May be the Key to Stopping Parkinson’s

Vertex Shells Out $950 Million for Semma Therapeutics

Like!! Really appreciate you sharing this blog post.Really thank you! Keep writing.
LikeLike
Thanks so much for the blog post.
LikeLike
I like the valuable information you provide in your articles.
LikeLike
Hey would you mind stating which blog platform you’re using? I’m going to start my own blog in the near future but I’m having a hard time selecting between BlogEngine/Wordpress/B2evolution and Drupal. The reason I ask is because your layout seems different then most blogs and I’m looking for something completely unique. P.S Sorry for being off-topic but I had to ask!
LikeLike
Hеy! I’m at ԝork surfing around your blog from my new
apрⅼe iphone! Jᥙst wanted to sаy I lⲟve reading your blog
and look forward to all your posts! Carry on the outstanding work!
LikeLike
Thanks for fantastic info I was looking for this info for my mission.
LikeLike
Your site is very helpful. Many thanks for sharing!
LikeLike
Best good quality USA proxies – DreamProxies.com invest in with 50 cut price!
LikeLike
Hi! I’m a Swiss Single Mom living in Charlotte, I found your article to be soooo Usefull!
LikeLike